Home
    Disclaimer
    ← Back to 2-FDCK
    2-FDCK molecular structure

    2-FDCK Stats & Data

    Dissociative Research-chemical
    2-fk 2f-ket 2f-ketamine Fluoroketamine 2-fl-2'-oxo-pcm 2-fluorodeschloroketamine 2f-dck 2fket
    NPS DataHub
    MW221.27
    FormulaC13H16FNO
    CAS111982-50-4
    IUPAC(2R)-2-(2-fluorophenyl)-2-(methylamino)cyclohexan-1-one
    SMILESCNC1(CCCCC1=O)c1ccccc1F
    InChIKeyPHFAGYYTDLITTB-CYBMUJFWSA-N
    Arylcyclohexylamines; 2021/6. Von Arylcyclohexylamin abgeleitete Verbindungen; 2022/6. Von Arylcyclohexylamin abgeleitete Verbindungen
    Psychoactive Class Dissociative

    History & Culture

    The synthesis of 2-fluorodeschloroketamine was first described in a 2013 scientific paper as part of a broader effort to synthesize and evaluate novel anesthetic compounds based on ketamine and its structural analogues. Despite this early documentation, the compound's origins as a recreational substance remain poorly established. It first emerged on the online research chemical market around 2017, where it was marketed as a legal alternative to ketamine. Its introduction followed the successful market entry of the related analogue deschloroketamine. The compound was first formally notified to the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) in 2016, alongside 65 other new psychoactive substances. Due to its relatively recent emergence, limited scientific research has been conducted on the compound. In January 2023, the Israeli biotechnology company Clearmind Medicine Inc. announced the completion of a preclinical study examining 2-fluorodeschloroketamine in a rat model of depression, with results suggesting the compound produced longer-lasting antidepressant effects compared to ketamine.

    Effect Profile

    Curated + 17 Reports
    Dissociative 5.4

    Strong dissociative depth, motor impairment, and mania with low insight

    Dissociative Depth×3
    10
    Mania / Compulsion×1
    8
    Insight / Novel Thought×2
    3
    Motor / Sensory Impairment×1
    10
    Based on reports from:
    Effect Index Entombed in Syrup — nervewing Bluelight Big & Dandy Thread Erowid Experience Reports PsychonautWiki 2-FDCK

    Duration Timeline

    Bluelight
    Onset Comeup Peak Offset After Effects
    Oral / Sublingual
    15 minutes - 1.0 hours
    45 minutes - 1.5 hours
    1-2 hours
    1-2 hours
    1-6 hours
    Total: 1-3 hours
    Insufflated
    4-19 minutes
    15-45 minutes
    1-2 hours
    1-2 hours
    1-6 hours
    Total: 1-3 hours
    Intramuscular
    4-10 minutes
    10-19 minutes
    1-2 hours
    1-2 hours
    1-6 hours
    Total: 1-3 hours
    Rectal
    10-30 minutes
    30 minutes - 1.0 hours
    1-2 hours
    1-2 hours
    1-6 hours
    Total: 1-3 hours
    Oral
    20-40 minutes hours
    1-3 hours
    Total: 1-3 hours

    Community Effects

    TripSit
    Positive
    hole

    Tolerance & Pharmacokinetics

    drugs.wiki

    Tolerance Decay

    Full tolerance 1d Half tolerance 21d Baseline ~28d

    Cross-Tolerances

    Ketamine
    80% ●○○
    Dextromethorphan
    80% ●○○
    PCP
    80% ●○○
    Methoxetamine
    80% ●○○
    3-MeO-PCP
    80% ●○○
    3-HO-PCP
    80% ●○○
    3-MeO-PCE
    80% ●○○
    3-HO-PCE
    80% ●○○

    Experience Report Analysis

    Erowid
    17 Reports
    2016–2025 Date Range
    17 With Age Data
    20 Effects Detected

    Demographics

    Gender Distribution

    Age Distribution

    Reports Over Time

    Effect Analysis

    Erowid

    Effects aggregated from 17 experience reports (17 Erowid)

    17 Reports
    20 Effects Detected
    8 Positive
    6 Adverse
    6 Neutral

    Effect Sentiment Distribution

    Confidence Distribution

    Positive Effects 8

    Music Enhancement 58.8% 70%
    Euphoria 52.9% 70%
    Color Enhancement 52.9% 70%
    Empathy 41.2% 70%
    Focus Enhancement 35.3% 70%
    Stimulation 35.3% 70%
    Tactile Enhancement 29.4% 70%
    Body High 29.4% 70%

    Adverse Effects 6

    Anxiety 58.8% 70%
    Motor Impairment 35.3% 70%
    Nausea 29.4% 70%
    Confusion 23.5% 70%
    Headache 17.6% 70%
    Increased Heart Rate 17.6% 70%

    Real-World Dose Distribution

    62K Doses

    From 45 individual dose entries

    Insufflated (n=23)

    Median: 25.0mg 25th: 17.0mg 75th: 61.5mg 90th: 110.0mg
    mg/kg median: 0.286 mg/kg 75th: 0.89

    Oral (n=13)

    Median: 25.0mg 25th: 20.0mg 75th: 30.0mg 90th: 38.0mg
    mg/kg median: 0.419 mg/kg 75th: 0.56

    Form / Preparation

    Most common forms and preparations reported

    Body-Weight Dosing

    Dose relative to body weight from reports with weight data

    Median: 0.436 mg/kg IQR: 0.278–2.0 mg/kg n=7

    Redose Patterns

    Redosing behavior across 15 reports

    66.7% Redosed
    2.7 Avg Doses
    15m Median Interval
    Read full reports on Erowid →

    Legal Status

    ECDD recommended addition to Schedule II of the Convention on Psychotropic Substances 1971 (October 2023)
    Country Status Notes
    Austria Illegal (NPSG) Controlled under the Neue-Psychoaktive-Substanzen-Gesetz (New Psychoactive Substances Act). Possession, production, and sale are prohibited.
    Belgium Illegal (blanket ban) Covered by blanket ban legislation on new psychoactive substances.
    Canada Potentially controlled (CDSA Schedule I) Not specifically listed in the Controlled Drugs and Substances Act but may be considered controlled under Schedule I as an analogue of phencyclidine or derivative of ketamine due to structural similarity.
    Germany Controlled (NpSG) Controlled under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) as of July 18, 2019. Production and import with intent to market, administration to others, and trading are punishable offenses. Possession is illegal but not subject to criminal penalty.
    Italy Schedule I (Tabella I) Listed as a controlled substance in Tabella I of Italian drug scheduling legislation. Production, sale, and possession are prohibited.
    Japan Illegal Controlled as a designated substance under Japanese drug legislation.
    Latvia Illegal Prohibited substance under national controlled substances legislation.
    Singapore Illegal Controlled under national drug legislation. Singapore maintains strict drug laws with severe penalties.
    Sweden Illegal Classified as a controlled substance under Swedish narcotics legislation.
    Switzerland Controlled (Verzeichnis E) Specifically named as a controlled substance under Verzeichnis E of Swiss narcotics scheduling.
    Turkey Illegal Classified as a controlled drug. Possession, production, supply, and import are prohibited.
    United Kingdom Class B Controlled under the Misuse of Drugs Act 1971. As an N-alkyl derivative of 2-amino-2-phenylcyclohexanone with a halide substituent in the phenyl ring, it falls under the arylcyclohexylamine generic clause added by S.I. 2013/239, effective February 26, 2013. Possession, production, supply, and import are illegal.
    ← Back to 2-FDCK